Clinical Trials Logo

Clinical Trial Summary

Despite recent advances in clinical and laboratory techniques of Assisted Reproductive Technology (ART), the pregnancy rate remains around 30% per cycle. It has been estimated that 50% to 75% of lost pregnancies are due to failure of implantation.

The process of implantation is a locally controlled paracrine/juxtacrine-mediated phenomenon. Successful implantation depends on the synchronized "cross-talk" between a functional blastocyst and a "receptive" endometrium. This process leads to apposition, attachment and invasion of embryos and subsequent normal placentation. So the objective of this study is investigate the impact of intrauterine injection of human chorionic gonadotropin (hCG) at the day of ovum pick-up on implantation and pregnancy rates in patients with recurrent implantation failure.


Clinical Trial Description

The endometrium can only support implantation during a discrete period of about 6 to 9 days after LH peak; termed the "window of implantation". During this period endometrial glandular epithelium is differentiated into a highly secretory state with the production of various cytokines and growth factors that facilitate implantation. In fact, several substances secreted from the embryo or the endometrium affect implantation. These include cyclic adenosine monophosphate, relaxin, gonadotropin, prostaglandin E2, and glycoprotein hormones.

Human chorionic gonadotropin (hCG) is the earliest blastocyst-derived signals received by the endometrium; it is transcribed as early as the 2-cell embryo stage. It is produced by the trophectodermal cells of the preimplantation blastocyst. Recent evidence suggests that hCG is also produced by the endometrial epithelial cells during the secretory.

It has been shown that intrauterine injection of hCG before embryo transfer significantly improves pregnancy rates in IVF/ICSI cycles. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03445910
Study type Interventional
Source Ain Shams University
Contact
Status Completed
Phase N/A
Start date February 20, 2018
Completion date July 30, 2018

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01933893 - Follicular Versus Luteal Pipelle in Repeated Implantation Failure Patients N/A
Recruiting NCT04497558 - The Clinical Efficiency of Tb-ERA in Chinese RIF Patients N/A
Recruiting NCT04867759 - Uterine Natural Killer (uNK) Cell Expression in Patients With Repeated ICSI Failures: A Multicenter Cohort Study
Completed NCT01493440 - Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure N/A
Not yet recruiting NCT02893722 - A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment Phase 1
Not yet recruiting NCT02967419 - The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure N/A
Completed NCT03405883 - Uterine Microbiome in Women With Repeated Implantation Failure and Normal Fertile Women
Completed NCT04698109 - Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gynecological Diseases
Recruiting NCT04533295 - The Effect of Acupuncture on IVF Pregnancy Outcomes for Women With RIF N/A